SITC 2021 Registration Now Open Participate in person or virtually at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021) taking place Nov. 10–14, 2021, at the Walter E. Washington Convention Center in Washington, D.C. Click here for more information about registering for SITC 2021.
Now AvailableRegular and YIA Abstract Titles and Authors With a record-breaking number of abstract submissions, SITC is excited to announce titles and authors for regular and Young Investigator Award (YIA) abstracts and posters that will be presented at the upcoming 36th Annual Meeting.
Download the new SITC Clinical Practice Guidelines (CPG) Mobile App! The first and only immunotherapy-specific clinical practice guidelines app featuring guideline content and expert panel recommendations in an easy-to-navigate format. The app includes interactive tools, bookmarks, and advanced search capabilities.Available for FREE for iOS and Android.
Cancer Immunotherapy Winter School, Jan. 24–28, 2022
SITC is pleased to host its fourth annual and first hybrid Cancer Immunotherapy Winter School, a comprehensive cancer immunotherapy education program, Jan. 24–28, 2022.
Call for Comment:SITC Lung Cancer and Mesothelioma Immunotherapy Clinical Practice Guideline
SITC invites public comment on the society's newest clinical practice guideline in development.Comments due on Oct. 25.
New SITC Clinical Practice Guidelines Published
JITC Increases Impact Factor to 13.751The Journal for ImmunoTherapy of Cancer's (JITC) Impact Factor makes JITC the highest ranked fully open access immunology journal and places it in the top 5% percent of all journals published in the category of immunology and top 7% in the category of oncology.
A series of eight two-hour online seminars will feature experts in a given subject area to provide an overview of the current scientific knowledge about an area of immunotherapy. An interactive Q&A session will follow the topic overview, providing attendees the opportunity to ask in-depth questions of the faculty as well as offering a forum for networking and initiation of collaborations with others working in a similar field.
Comprised of several authoritative reviews of COVID-19 and Cancer Immunotherapy, this series, edited by Paolo Antonio Ascierto, MD and Jason D. Goldman, MD, MPH, will explore basic insights into the immunology of the novel coronavirus, repurposing of immune-based therapies including the effects of immune-oncology agents, and the affected cancer populations.
Join Alan Hutson, PhD, and the thousands of other cancer immunotherapy professionals who proudly call themselves SITC members.
Explore resources and educational opportunities for cancer patients and those who advocate for them.
Track the latest advancements and educational opportunities in tumor immunology and cancer immunotherapy.
Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.
Hi Todd, We would love to have your chapter but the deadline for book chapters has passed. However, if you can get your contribution by October 25, 2021, we should be able to review it for inclusion. Please let me know. Priya Hays
This could be interesting. Happy to join. ------------------------------ Raphael Ognar MS, MBA CEO & Co-Founder NKILT Therapeutics Springfield NJ ------------------------------
Hi Francesca I am happy to join in this group... Best, Jayadev ------------------------------ Jayadev Mavuluri PhD Postdoc St.Jude Children's Research Hospital Memphis TN ------------------------------
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com